Tumor molecular profiling of responders and non-responders following pembrolizumab monotherapy in chemotherapy resistant advanced cervical cancer

Optimal treatment for advanced cervical cancer after first line chemotherapy remains undefined. Immune checkpoint inhibition with pembrolizumab, a programmed cell death protein 1(PD-1) inhibitor, is under investigation. We analyzed the micro-environmental and molecular genetic profile of tumors from...

Descripción completa

Detalles Bibliográficos
Autores principales: Ngoi, N.Y.L., Heong, V., Lee, X.W., Huang, Y.Q., Thian, Y.L., Choo, B.A., Lim, D., Lim, Y.W., Lim, S.E., Ilancheran, A., Soong, R., Tan, D.S.P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5993533/
https://www.ncbi.nlm.nih.gov/pubmed/29892689
http://dx.doi.org/10.1016/j.gore.2018.01.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5993533/
https://www.ncbi.nlm.nih.gov/pubmed/29892689
http://dx.doi.org/10.1016/j.gore.2018.01.009

Ejemplares similares